Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan dosing by UGT1A1 genotype in metastatic colorectal cancer
NCT01523431Phase 3Completed
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Mar 2012
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan in colorectal cancer (metastatic) (mCRC), sponsored by 307 Hospital of the People's Liberation Army. Started Mar 2012; status: completed.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01523431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01523431.